Advanced search
Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Email Registration
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Novavax, Inc.
  6. News
  7. Summary
    NVAX   US6700024010

NOVAVAX, INC.

(NVAX)
  Report
Delayed Nasdaq  -  04:00:00 2023-01-31 pm EST
10.91 USD   +2.44%
01/26FDA advisers back the same COVID vaccine for initial shots, boosters
RE
01/26Novavax needs 6 months to produce annual COVID shots that match new variants
RE
01/25Novavax Announces Grant of Inducement Awards Pursuant to Nasdaq Listing Rule 5635(c)(4)
PR
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

B. Riley Lowers Novavax's PT to $83 From $126 to Reflect Current Realities of COVID Booster Market Dynamics, Cuts Near-Term Estimates; Maintains Buy Rating

10/14/2022 | 09:05am EST
share with twitter
share with LinkedIn
share with facebook


© MT Newswires 2022
All news about NOVAVAX, INC.
01/26FDA advisers back the same COVID vaccine for initial shots, boosters
RE
01/26Novavax needs 6 months to produce annual COVID shots that match new variants
RE
01/25Novavax Announces Grant of Inducement Awards Pursuant to Nasdaq Listing Rule 5635(c)(4)
PR
01/20River Private Wealth announces new round of investment in Novavax, Inc
AQ
01/20Novavax, Inc. announced that it has received $6.75 million in funding from River Privat..
CI
01/18Novavax Says South Korea Partner Obtained Approval for Use of COVID-19 Vaccine as Adult..
MT
01/18Novavax COVID-19 Jab Gets South Korea's OK as Booster for Adults
MT
01/18Novavax Nuvaxovid COVID-19 Vaccine Approved in South Korea as an Adult Booster
PR
01/10MarketScreener's World Press Review: January 10
MS
01/10North American Morning Briefing: More Hawkish Fed -2-
DJ
More news
Analyst Recommendations on NOVAVAX, INC.
More recommendations
Financials (USD)
Sales 2022 1 947 M - -
Net income 2022 -535 M - -
Net cash 2022 1 455 M - -
P/E ratio 2022 -1,53x
Yield 2022 -
Capitalization 938 M 938 M -
EV / Sales 2022 -0,27x
EV / Sales 2023 -0,41x
Nbr of Employees 1 541
Free-Float 98,6%
Chart NOVAVAX, INC.
Duration : Period :
Novavax, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVAVAX, INC.
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Last Close Price 10,91 $
Average target price 55,33 $
Spread / Average Target 407%
EPS Revisions
Managers and Directors
John C.s Jacobs President, Chief Executive Officer & Director
James Patrick Kelly Chief Financial Officer, Treasurer & Executive VP
James F. Young Chairman
Gregory M. Glenn President-Research & Development
Biegie Lee Chief Information Officer & Senior Vice President
Sector and Competitors
1st jan.Capi. (M$)
NOVAVAX, INC.6.13%916
MODERNA, INC.0.70%69 487
LONZA GROUP AG17.81%42 878
IQVIA HOLDINGS INC.10.44%42 029
ALNYLAM PHARMACEUTICALS, INC.-5.15%27 731
SEAGEN INC.8.54%25 989